Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014
Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00298155 (Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer), which is not on this map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Who cites it
46 citing papers in PubMed, 87 citations in OpenAlex.
- Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.The Journal of urology · 2021Trial
- Loss ofJCO precision oncology · 2021Trial
- Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease.Breast cancer research and treatment · 2019Trial
- Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.Endocrine-related cancer · 2017Trial
- Neoadjuvant Enzalutamide Prior to Prostatectomy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Short-Term Estrogen Withdrawal Increases Adiposity in Healthy Men.The Journal of clinical endocrinology and metabolism · 2016Trial
- Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone.The Journal of clinical endocrinology and metabolism · 2016Trial
- External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.International journal of radiation oncology, biology, physics · 2015Trial
- Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Trial
- Outcomes of Neoadjuvant Radiotherapy Followed by Robotic Radical Prostatectomy in High-Risk Locally Advanced Prostate Cancer: A Prospective Pilot Study.Annals of surgical oncology · 2026Article
- Repurposing antifungal drugs for cancer therapy.Journal of advanced research · 2023Review
- The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.JNCI cancer spectrum · 2022Article
- Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.Nature reviews. Urology · 2021Review
- In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.Journal of biomolecular structure & dynamics · 2021Article
- Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.The Prostate · 2021Article
- Determination of Intraprostatic and Intratesticular Androgens.International journal of molecular sciences · 2021Review
- In silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry.Turkish journal of biology = Turk biyoloji dergisi · 2021Article
- Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2020Review
- The role of adrenal derived androgens in castration resistant prostate cancer.The Journal of steroid biochemistry and molecular biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
Abstract
purposeLigand-mediated activation of the androgen receptor (AR) is critical for prostate cancer (PCa) survival and proliferation. The failure to completely ablate tissue androgens may limit suppression of PCa growth. We evaluated combinations of CYP17A and 5-α-reductase inhibitors for reducing prostate androgen levels, AR signaling, and PCa volumes. PATIENTS AND
methodsThirty-five men with intermediate/high-risk clinically localized PCa were randomly assigned to goserelin combined with dutasteride (ZD), bicalutamide and dutasteride (ZBD), or bicalutamide, dutasteride, and ketoconazole (ZBDK) for 3 months before prostatectomy. Controls included patients receiving combined androgen blockade with luteinizing hormone-releasing hormone agonist and bicalutamide. The primary outcome measure was tissue dihydrotestosterone (DHT) concentration.
resultsProstate DHT levels were substantially lower in all experimental arms (0.02 to 0.04 ng/g v 0.92 ng/g in controls; P < .001). The ZBDK group demonstrated the greatest percentage decline in serum testosterone, androsterone, and dehydroepiandrosterone sulfate (P < .05 for all). Staining for AR and the androgen-regulated genes prostate-specific antigen and TMPRSS2 was strongly suppressed in benign glands and moderately in malignant glands (P < .05 for all). Two patients had pathologic complete response, and nine had ≤ 0.2 cm(3) of residual tumor (defined as a near-complete response), with the largest numbers of complete and near-complete responses in the ZBDK group.
conclusionAddition of androgen synthesis inhibitors lowers prostate androgens below that achieved with standard therapy, but significant AR signaling remains. Tissue-based analysis of steroids and AR signaling is critical to informing the search for optimal local and systemic control of high-risk prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.